It’s only fair to share… Methyl 3-amino-2-thiophenecarboxylate Molecular Formula C6H7NO2S Average mass 157.190 Da 2-Thiophenecarboxylic acid, 3-amino-, methyl ester Cas 22288-78-4 MW 157.19, MF C6 H7 N O2 S 1H NMR CDCL3 13C NMR CDCL3 IR MASS 1H NMR PREDICT 13C NMR PREDICT SYNTHESIS 1 By Pokhodylo, Nazariy T. et alFrom Synthetic Communications, 44(7), 1002-1006; 2014 2-Propenenitrile, …
Category «Uncategorized»
Synthesis of ureas in the bio-alternative solvent Cyrene
It’s only fair to share… Synthesis of ureas in the bio-alternative solvent Cyrene Green Chem., 2017, Advance Article DOI: 10.1039/C7GC00908A, Communication Liam Mistry, Kopano Mapesa, Thomas W. Bousfield, Jason E. Camp The bio-alternative solvent Cyrene was shown to be an alternative to toxic oil-derived solvents for the synthesis of ureas. N-Phenylpyrrolidine-1-carboxamide (6a) 1 Method A: …
Dr. Vinayak Pagar( GUEST BLOGGER) Development of a Povarov Reaction/Carbene Generation Sequence for Alkenyldiazocarbonyl Compounds
It’s only fair to share… Discussing my paper…….. Metal-catalyzed cycloadditions of alkenyldiazo reagents are useful tools to access carbo- and heterocycles.[1] These diazo compounds are chemically sensitive toward both Brønsted orLewis acids. Their reported cycloadditions rely heavily on the formation of metal carbenes to initiate regio- and stereoselective [3+n] cycloadditions (n=2–4) with suitable dipolarophiles.[2–4] A noncarbene route was postulated for a …
An insight into the therapeutic potential of quinazoline derivatives as anticancer agents
It’s only fair to share… The Food and Drug Administration (FDA) has approved several quinazoline derivatives for clinical use as anticancer drugs. These include gefitinib, erlotinib, lapatinib, afatinib, and vandetanib (Fig.1) [43]. Gefitinib (Iressa®) was approved by the FDA in 2003 for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in …
BLU 285
It’s only fair to share… BLU-285 CAS 1703793-34-3 Molecular FormulaC26H27FN10 Average mass498.558 Da (1S)-1-(4-Fluorophenyl)-1-(2-{4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-1-piperazinyl}-5-pyrimidinyl)ethanamine 5-Pyrimidinemethanamine, α-(4-fluorophenyl)-α-methyl-2-[4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-1-piperazinyl]-, (αS)- 5-Pyrimidinemethanamine, α-(4-fluorophenyl)-α-methyl-2-[4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-1-piperazinyl]-, (αS)- Originator Blueprint Medicines Class Antineoplastics; Skin disorder therapies; Small molecules Mechanism of Action Platelet-derived growth factor alpha receptor modulators; Proto oncogene protein c-kit inhibitors Orphan Drug Status Yes – Systemic mastocytosis; Gastrointestinal stromal tumours Phase I Gastrointestinal stromal tumours; Solid tumours; …
Tamibarotene, тамибаротен , تاميباروتان , 他米巴罗汀 ,
It’s only fair to share… Tamibarotene тамибаротен , تاميباروتان , 他米巴罗汀 , 94497-51-5 CAS Molecular FormulaC22H25NO3 Average mass351.439 Da 4-(((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino)carbonyl)benzoic Acid, Tamibarotene 4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbamoyl]benzoic acid Benzoic acid, 4-[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]carbonyl]- Amnolake® Amnoleuk Benzoic acid, 4-(((5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino)carbonyl)- BR-72889 C061133 DH6940000 MFCD00866188 [MDL number] N-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl)-2-naphthyl)terephthalamic acid QA-6963 retinobenzoic acid Am 80 Am 80 (pharmaceutical) Amnolake NSC 608000 RR 110 Hisao Ekimoto, “TAMIBAROTENE CAPSULE PREPARATION.” U.S. Patent …
PF 2562
It’s only fair to share… PF 2562 CAS 1609258-91-4 MF C19 H17 N5 O MW 331.37 1H-Pyrazolo[4,3-c]pyridine, 4-[4-(4,6-dimethyl-5-pyrimidinyl)-3-methylphenoxy]- Inventors Jennifer Elizabeth Davoren, Amy Beth Dounay, Ivan Viktorovich Efremov, David Lawrence Firman Gray, Scot Richard Mente, Steven Victor O’Neil, Bruce Nelsen Rogers, Chakrapani Subramanyam, Lei Zhang Original Assignee Pfizer Inc Jennifer Elizabeth Davoren Principal Scientist at Pfizer …
GSK 3008348
It’s only fair to share… GSK 3008348 (3S)-3-[3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl]-4-{(3S)-3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl}butanoic acid cas 1629249-33-7 1-Pyrrolidinebutanoic acid, β-[3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-, (βS,3R)- (S)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid (βS,3R)-β-[3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl]-3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinebutanoic acid Molecular Formula C29H37N5O2 Average mass 487.636 Da CAS Number: 1629249-40-6 Molecular Weight: 524.1 Molecular Formula: C29H38ClN5O2 Originator GlaxoSmithKline Mechanism of Action Integrin alphaV antagonists Phase I Idiopathic pulmonary fibrosis 06 Mar 2017 GlaxoSmithKline plans a phase I trial for Idiopathic pulmonary …
AZD 9567
It’s only fair to share… AZD 9567 CAS 1893415-00-3 1893415-64-9 as MONOHYDRATE 2,2-Difluoro-N-[(1R,2S)-3-methyl-1-[[1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1H-indazol-5-yl]oxy]-1-phenylbutan-2-yl]propanamide Propanamide, N-[(1S)-1-[(R)-[[1-(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)-1H-indazol-5-yl]oxy]phenylmethyl]-2-methylpropyl]-2,2-difluoro- 2,2-difluoro-N-[(1R,2S)-3-methyl-1-[1-(1-methyl-6-oxopyridin-3-yl)indazol-5-yl]oxy-1-phenylbutan-2-yl]propanamide 2,2-difluoro- V-[(lR,25)-3-methyl-l-{[l-(l-methyl-6-oxo-l,6-dihydropyridin-3-yl)-lH-indazol-5-yl]oxy}-l-phenylbutan-2-yl]propanamide MF C27 H28 F2 N4 O3, MF 494.533 AstraZeneca INNOVATOR AZD-9567, a glucocorticoid receptor modulator, is in early clinical development at AstraZeneca in healthy male volunteers. Phase I Rheumatoid arthritis Originator AstraZeneca Class Antirheumatics Mechanism of Action Glucocorticoid receptor modulators 01 Sep 2016 AstraZeneca completes a …
PF 06648671
It’s only fair to share… PF-06648671, PF 06648671, PF-6648671 CAS 1587727-31-8 C25 H23 Cl F4 N4 O3 538.92 2H-Pyrido[1,2-a]pyrazine-1,6-dione, 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydro-2-furanyl]ethyl]-3,4-dihydro-7-(4-methyl-1H-imidazol-1-yl)- Phase I Alzheimer’s disease Originator Pfizer 01 Nov 2016 Pfizer completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02883114) 01 Oct 2016 Pfizer completes a phase I trial in Healthy volunteers in Belgium (NCT02440100) 01 …